



powered by Cea

Provided by Clinical Care Options, LLC

Actionable Biomarkers in Lung Cancer: Clinical Applications for Nursing Practice

Saturday, September 10, 2022 | 1:50 PM PT
GLAONS – 6th Annual Oncology Care Summit
Los Angeles, CA

Supported by educational grants from AstraZeneca; Lilly; Merck Sharp & Dohme Corp.;
Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.
and Sanofi Genzyme.



Program Co-Chair

Beth Sandy, MSN, CRNP

Nurse Practitioner

Abramson Cancer Center

University of Pennsylvania

Philadelphia, Pennsylvania

Beth Sandy, MSN, CRNP, has disclosed that she has received consultant/advisor/speaker fees from Amgen, AstraZeneca, Janssen, Jazz, Merck, and Takeda.

Program Co-Chair

Elizabeth S. Waxman, BSN, MSN, ANP-BC

Nurse Practitioner

Thoracic/Head & Neck Medical Oncology

The University of Texas MD Anderson Cancer Center

Houston, Texas

Elizabeth S. Waxman, BSN, MSN, ANP-BC, has no relevant conflicts of interest to report.

Faculty

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP, FAAN

Associate Professor

Coordinator of Oncology Concentration

Yale University School of Nursing

Oncology Nurse Practitioner

Medical Oncology

Smilow Cancer Hospital at Yale-New Haven

New Haven, Connecticut

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP, FAAN, has no relevant conflicts of interest to report.

Faculty

Kayla Haines, MSN, APRN, FNP-C

Nurse Practitioner

Oncology

Boca Raton, FL

Kayla Haines, MSN, APRN, FNP-C, has disclosed that she has received consultant/advisor/speaker fees from G1 Therapeutics, Janssen Oncology, Novartis, and Takeda and is an independent contractor for PrecisCA.

Faculty

Elizabeth Krueger, NP

Nurse Practitioner

Thoracic Oncology

Massachusetts General Hospital Cancer Center

Boston, Massachusetts

Elizabeth Krueger, NP, has no relevant conflicts of interest to report.

Faculty

Blanca Ledezma, MSN, NP

Nurse Practitioner, Hematology/Oncology

UCLA Santa Monica

Santa Monica, California

Blanca Ledezma, MSN, NP, has disclosed that she has received speaker fees from Amgen, AstraZeneca, Eisai, Helsinn, and Lilly.

Faculty

Julie C. Martin, DNP, AOCN, NP

Clinical Assistant Professor

University of South Carolina School of Medicine Greenville

Director, Cancer Research

Prisma Health

Greenville, South Carolina

Julie C. Martin, DNP, AOCN, NP, has disclosed that she has received consultant/advisor/speaker fees from Epizyme and is an independent contractor for the Oncology Nursing Society.

Faculty

Rasheda Persinger, MSN, AGNP-C, AOCNP

Lead Nurse Practitioner, Medical Oncology

Johns Hopkins

Washington, DC

Rasheda Persinger, MSN, NP-C, has disclosed that she has received consultant/advisor/speaker fees from AstraZeneca, Guardant Health, and Pfizer.

Disclosure of Conflicts of Interest

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Staff Disclosures

The *planners/managers* reported the following relationships:

Kelly Brandt, PharmD, BCOP, BCPS; Kristen Rosenthal, PhD; Gordon Kelley; Timothy A. Quill, PhD; Krista Marcello; June Wasserstrom; and **Kevin Obholz, PhD,** have no relevant conflicts of interest to report.

Jim Mortimer has disclosed he had individually publicly traded stocks/stock options in AstraZeneca.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Goal

The goal of this activity is to improve oncology nurses' ability to educate and optimally care for patients with lung cancer who have actionable biomarkers.

Target Audience

This program is intended for oncology nurses and other healthcare professionals who care for patients with lung cancer.

Learning Objectives

At the conclusion of this activity, learners should be able to:

- Evaluate new and emerging predictive biomarkers that guide precision treatment decisions in patients with NSCLC
 - Apply available clinical data and new therapeutic options for the individualized treatment of patients with actionable biomarkers
 - Discuss with patients the benefits and limitations of biomarker testing and targeted therapies, along with practical considerations such as comorbidities and adherence
 - Develop a proactive management plan for AEs associated with recently approved targeted agents and novel combinations
-

Accreditation Information



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Activity is 1.0 contact hour.

Please refer to this card
for instructions to receive
CE credit and for
additional resources



Therapeutically Actionable Biomarkers in Lung Cancer: Clinical Applications for Nursing Practice

EVALUATION AND REQUEST FOR CREDIT

Below are instructions for evaluating and requesting credit for the CE-certified live meeting.

- Go to www.clinicaloptions.com/event/LungONSLocal2022Eval to access the online evaluation and credit request system. You can use any computer or Internet interactive device to complete the evaluation and credit request process.
- View and print your certificate upon completion of the online evaluation.

You have **30 days** before the link expires to complete the evaluation details and print your certificate.

CLINICAL RESOURCES

Download slidesets from the live event

(available at: www.clinicaloptions.com/LungONSLocal2022Slides)

On-demand webcast

(available at: www.clinicaloptions.com/LungONSLocal2022Webcast)

Pocket guide

(available at: www.clinicaloptions.com/LungONSLocal2022PG)



CCOONC22022



powered by CEA

Downloadable Slides & Evaluation Link

- Slides from this meeting are now available on the CCO website

clinicaloptions.com/LungONSLocal2022Slides

- Evaluation link will be available on the CCO website after the program

clinicaloptions.com/LungONSLocal2022Eval

Go Online for More CCO Coverage of Lung Cancer!

CE-certified on-demand webcast of a live workshop (*coming soon*)

Downloadable slideset with slides from today's presentation (*available now*)

Downloadable clinical resource (*coming soon*)

clinicaloptions.com/LungONSLocal2022Program

